Microbot Medical Inc. (MBOT) · Oct 23, 2026 · Other events
Commercial outreach
Microbot Medical’s conference announcement supports its LIBERTY sales push, but reports no new orders, revenue, customers, or commercial milestone.
Microbot is in early commercialization, not yet at a scaled-sales milestone. The company has moved LIBERTY from limited release toward full-market commercialization, while expanding its U.S. sales footprint and pursuing hospital adoption across multiple territories.
This filing keeps the sales funnel active, but does not advance it measurably. Management will attend SIR EDGE 2026 alongside the ACIR conference to meet physicians, hospital administrators, and Value Analysis Committees as it expands its national sales effort. 〔0〕
The key limitation is the absence of a commercial conversion. The release discusses prospective customers, new leads, demonstrations, and existing leads moving through the VAC process, but announces no purchase order, hospital win, revenue figure, or committed deployment. 〔1〕 That makes the update directionally consistent with the company’s stated commercialization plan rather than a new proof of adoption.
Bottom line: This is routine business-development activity that supports Microbot’s LIBERTY rollout but does not materially change the story until conference interest converts into hospital orders or deployments.
SIR EDGE conference, October 25–27, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!